The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Scientists now believe that Brazil has one of the overlooked and underexplored populations when it comes to longevity. As per ...

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

J&J successfully acquired Halda Therapeutics for $3.05bn integrating Halda’s RIPTAC platform into J&J’s oncology portfolio.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

What Is Changing In The Legend Biotech Story Right Now Legend Biotech’s latest model tweaks reflect refinement rather than a ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...